By 2 months of age , 22 of 25 ( 88 % ) of 2 dose recipients had detectable IgG antibody to PT ( IgG PT ) compared with 9 of 21 ( 43 % ) who received a birth dose only and 3 of 20 ( 15 % ) of controls .
